The anti-sense oligonucleotide (ASO) treatment tofersen (QALSODY) has beneficial clinical effects and biomarker readouts, but applies only to the ~ 2% of ALS patients who harbor a SOD1 mutation [6]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.